




RealRate

PHARMACEUTICAL 2020

Nanoviricides INC
Rank 130 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Nanoviricides INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nanoviricides INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 185% points. The greatest weakness of Nanoviricides INC is the variable Assets, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 51% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	2,825
Cost of Goods Sold	0
Intangible Assets	367
Liabilities, Current	2,848
Liabilities, Non-Current	0
Other Assets	29
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	235
Other Revenues	0
Property and Equipment	10,227
Research and Development	5,922
Selling, General and Administrative Expense	2,738

Output Variable	Value in 1000 USD
Assets	13,449
Liabilities	2,848
Expenses	8,660
Revenues	0
Stockholders Equity	10,600
Net Income	-8,424
Comprehensive Net Income	-8,424
BaseVar	12,596
ECR before LimitedLiability	180%
Economic Capital Ratio	289%